ColoVantage®
Middle aged couple spending time relaxing

ColoVantage® is a convenient blood test that aids in the detection of colorectal cancer in patients non-adherent to current testing approaches.

Lung Cancer Mutation Panel
mature couple on a sunny day holding umbrella

EGFR, KRAS and EML4-ALK Predict Eligibility for NSCLC Targeted Therapies. Help assess your patients with NSCLC being considered for treatment with an EGFR TKI.

Learn more about Quest Vantage hereditary cancer testing
Doctor talking to patient about testing for BRCA1 and BRCA2 genetics.

Quest Vantage offers a portfolio of hereditary cancer tests with multiple test options for focused and comprehensive genetic testing and services. The insights provided by Quest Vantage can help patients and healthcare providers identify appropriate and proven strategies to help reduce these risks.

Lung cancer test summary

Test highlight- ROS1

Lung cancer is the leading cause of cancer-related deaths in the United States, and Non-small cell lung cancer (NSCLC) accounts for over 85% of all cases. Some NSCLC patients may benefit from targeted drug therapy based on specific genetic alterations in their tumors. Detection of ROS1 rearrangements in patients with NSCLC suggests eligibility for treatment with the tyrosine kinase inhibitor crizotinib.

For more details of ROS1 test, please see the test summary.

male employee at podium

For Continuing Education Credit

Advances in Cervical Cancer Screening and a New Approach to the Pelvic Mass. Darren Wheeler, MD discusses recent advances regarding human papillomavirus and Pap co-testing as well as emerging technologies and clinical approaches for ovarian cancer.

Quest homepage

For continuing education credit

Molecular Diagnostics in Lung Cancer (audio). Review of the genetic mutations often found in patients with lung cancer, impact on diagnosis and treatment, and appropriate use.

Quest homepage

Diagnostic advances in colorectal cancer screening

To leave this site and access a continuing medical education activity on colorectal cancer developed by and developed independently of Quest Diagnostics: